Laraia Luca, Stokes Jamie, Emery Amy, McKenzie Grahame J, Venkitaraman Ashok R, Spring David R
Department of Chemistry, University of Cambridge , Cambridge CB2 1EW, U.K. ; MRC Cancer Unit, University of Cambridge , Hutchison/MRC Research Centre, Biomedical Campus, Cambridge CB2 0XZ, U.K.
MRC Cancer Unit, University of Cambridge , Hutchison/MRC Research Centre, Biomedical Campus, Cambridge CB2 0XZ, U.K.
ACS Med Chem Lett. 2014 Feb 24;5(5):598-603. doi: 10.1021/ml5000564. eCollection 2014 May 8.
Tubulin modulating agents such as the taxanes are among the most effective antimitotic cancer drugs, although resistance and toxicity present significant problems in their clinical use. However, most tubulin modulators are derived from complex natural products, which can make modification of their structure to address these problems difficult. Here, we report the discovery of new antimitotic compounds with simple structures that can be rapidly synthesized, through the phenotypic screening of a diverse compound library for the induction of mitotic arrest. We first identified a compound, which induced mitotic arrest in human cells at submicromolar concentrations. Its simple structure enabled rapid exploration of activity, defining a biphenylacetamide moiety required for activity, A family of analogues was synthesized, yielding optimized compounds that caused mitotic arrest and cell death in the low nanomolar range, comparable to clinically used antimitotic agents. These compounds can be synthesized in 1-3 steps and good yields. We show that one such compound targets tubulin, partially inhibiting colchicine but not vinblastine binding, suggesting that it acts allosterically to the known colchicine-binding site. Thus, our results exemplify the use of phenotypic screening to identify novel antimitotic compounds from diverse chemical libraries and characterize a family of biphenylacetamides (biphenabulins) that show promise for further development.
诸如紫杉烷类的微管蛋白调节剂是最有效的抗有丝分裂癌症药物之一,尽管耐药性和毒性在其临床应用中带来了重大问题。然而,大多数微管蛋白调节剂源自复杂的天然产物,这使得对其结构进行修饰以解决这些问题变得困难。在此,我们报告通过对一个多样化化合物库进行表型筛选以诱导有丝分裂停滞,发现了具有可快速合成的简单结构的新型抗有丝分裂化合物。我们首先鉴定出一种化合物,它在亚微摩尔浓度下就能诱导人细胞发生有丝分裂停滞。其简单的结构使得能够快速探索活性,确定了活性所需的联苯乙酰胺部分。合成了一系列类似物,得到了在低纳摩尔范围内引起有丝分裂停滞和细胞死亡的优化化合物,与临床使用的抗有丝分裂药物相当。这些化合物可以通过1 - 3步以良好的产率合成。我们表明,其中一种这样的化合物靶向微管蛋白,部分抑制秋水仙碱但不抑制长春碱结合,这表明它对已知的秋水仙碱结合位点起变构作用。因此,我们的结果例证了利用表型筛选从多样化化学库中鉴定新型抗有丝分裂化合物,并表征了一类显示出有进一步开发前景的联苯乙酰胺(联苯布灵)。